Podium Presentation
Thursday, March 13
Title: Ultra-Sensitive MRD utilization to overcome challenges in Early-Stage Cancer recurrence detection
- NeXT Personal is an advanced tumor-informed liquid biopsy assay with ultra-sensitive detection down to 1PPM
- Ultrasensitive detection with this bespoke whole genome sequencing based assay improves detection of ctDNA at baseline and during follow-up with increased lead time over clinical relapse
- Clinical studies in early-stage lung and breast cancer establish that NeXT Personal MRD detection is strongly correlated with patient outcome.
Track: Advances in Immunotherapy and Immuno-Oncology Programme
Session: Predictive Models, Tools & Biomarkers Approaches for Pre-Clinical & Clinical Evaluation and Translational Development
Location/Time: Bourg Suite (Conference Room 8) / 3:05PM – 3:30PM (PST)
About the Presenter:
Dr. Christelle Johnson joined Personalis in 2015 as Field Applications Scientist with 10 years of research experience in immuno-oncology and genomics. In her current role, Christelle provides technical and scientific support on Personalis’ portfolio for Biopharma.
Christelle completed her postdoctoral studies at Harvard Medical School and Cornell University investigating the role of the tumor microenvironment and metabolic pathways in cancer growth and progression. She received her PhD in Cancer Immunology from the University of Louisville School of Medicine.
